anurajms/meta_analysis huggingface dataset:
Provide patient population that should be included in the study
Saline irrigation for the management of skin extravasation injury in neonates
1. Neonate 2. Birth to 1 mo 3. Catheter Site Extravasation
Provide patient population that should be included in the study
Antibiotics for neonates born through meconium‐stained amniotic fluid
1. Neonate 2. Term infant (37-41 weeks) 3. Birth to 1 mo 4. Asymptomatic 5. Meconium Stained Liquor 6. Preterm Infant 7. Meconium Aspiration Syndrome
Provide patient population that should be included in the study
Orotracheal intubation in infants performed with a stylet versus without a stylet
1. Neonate 2. Birth to 1 mo 3. Intubation
Provide patient population that should be included in the study
Clonidine for sedation and analgesia for neonates receiving mechanical ventilation
1. Term infant (37-41 weeks) 2. Birth to 1 mo 3. Preterm Infant 4. Mechanical ventilation
Provide patient population that should be included in the study
Effects of targeting lower versus higher arterial oxygen saturations on death or disability in preterm infants
1. Extremely Preterm Infant (<28 weeks) 2. Birth to 1 mo
Provide patient population that should be included in the study
Repeated lumbar or ventricular punctures in newborns with intraventricular haemorrhage
1. Infant 1 to 23 mo 2. Intraventricular Hemorrhage 3. Birth to 1 mo
Provide patient population that should be included in the study
Frenotomy for tongue‐tie in newborn infants
1. Infant 1 to 23 mo 2. Breast Feeding Problem (infant) 3. Nipple Pain 4. Birth to 1 mo 5. Tongue Tie
Provide patient population that should be included in the study
Neonatal vitamin A supplementation for the prevention of mortality and morbidity in term neonates in low and middle income countries
1. Term infant (37-41 weeks) 2. Birth to 1 mo
Provide patient population that should be included in the study
Skin‐to‐skin care for procedural pain in neonates
1. Term infant (37-41 weeks) 2. Procedural Pain 3. Birth to 1 mo 4. Preterm Infant
Provide patient population that should be included in the study
Topical anaesthesia for needle‐related pain in newborn infants
1. Term infant (37-41 weeks) 2. Birth to 1 mo 3. Preterm Infant 4. Needle Stick/puncture
Provide patient population that should be included in the study
Intravenous midazolam infusion for sedation of infants in the neonatal intensive care unit
1. Neonate 2. Sedation During Medical Procedure 3. Birth to 1 mo 4. Intensive Care
Provide patient population that should be included in the study
Cromolyn sodium for the prevention of chronic lung disease in preterm infants
1. Birth to 1 mo 2. Preterm Infant
Provide patient population that should be included in the study
Body positioning for spontaneously breathing preterm infants with apnoea
1. Recurrent Apnea Of Newborn 2. Birth to 1 mo 3. Preterm Infant
Provide patient population that should be included in the study
Nitric oxide for respiratory failure in infants born at or near term
1. Hypoxemia 2. Term infant (37-41 weeks) 3. Birth to 1 mo 4. Late Preterm Infant (34-36 weeks)
Provide patient population that should be included in the study
Early administration of inhaled corticosteroids for preventing chronic lung disease in very low birth weight preterm neonates
1. Dependence On Ventilator 2. Birth to 1 mo 3. Very Low Birth Weight Infant 4. Preterm Infant
Provide patient population that should be included in the study
Inhaled nitric oxide for respiratory failure in preterm infants
1. Birth to 1 mo 2. Respiratory Failure 3. Preterm Infant
Provide patient population that should be included in the study
Heparin for the treatment of thrombosis in neonates
1. Arterial Thrombosis 2. Neonate 3. Venous Thrombosis 4. Birth to 1 mo
Provide patient population that should be included in the study
Infant position in neonates receiving mechanical ventilation
1. Term infant (37-41 weeks) 2. Birth to 1 mo 3. Preterm Infant 4. Mechanical ventilation
Provide patient population that should be included in the study
Synchronized mechanical ventilation for respiratory support in newborn infants
1. Neonate 2. Assisted Breathing 3. Birth to 1 mo
Provide patient population that should be included in the study
Responsive versus scheduled feeding for preterm infants
1. Enteral nutrition 2. Birth to 1 mo 3. Preterm Infant
Provide patient population that should be included in the study
Cup feeding versus other forms of supplemental enteral feeding for newborn infants unable to fully breastfeed
1. Term infant (37-41 weeks) 2. Birth to 1 mo 3. Breastfeeding Problem In The Newborn 4. Preterm Infant
Provide patient population that should be included in the study
Early additional food and fluids for healthy breastfed full‐term infants
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Infant 1 to 23 mo 4. Young Adult 19-24 years 5. Birth to 1 mo 6. Breast Fed 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Instruments for assessing readiness to commence suck feeds in preterm infants: effects on time to establish full oral feeding and duration of hospitalisation
1. Birth to 1 mo 2. Preterm Infant
Provide patient population that should be included in the study
Sucrose for analgesia in newborn infants undergoing painful procedures
1. Term infant (37-41 weeks) 2. Procedural Pain 3. Birth to 1 mo 4. Preterm Infant
Provide patient population that should be included in the study
Epinephrine for transient tachypnea of the newborn
1. Transitory Tachypnea Of Newborn 2. Term infant (37-41 weeks) 3. Birth to 1 mo 4. Preterm Infant
Provide patient population that should be included in the study
Heparin for the prevention of intraventricular haemorrhage in preterm infants
1. Very Preterm Infant (28-31 weeks) 2. Extremely Preterm Infant (<28 weeks) 3. Birth to 1 mo
Provide patient population that should be included in the study
Co‐bedding in neonatal nursery for promoting growth and neurodevelopment in stable preterm twins
1. Twins - Both Live Born 2. Birth to 1 mo 3. Preterm Infant
Provide patient population that should be included in the study
Antimicrobial dressings for the prevention of catheter‐related infections in newborn infants with central venous catheters
1. Neonate 2. Birth to 1 mo 3. Central Venous Catheterisation 4. Intensive Care
Provide patient population that should be included in the study
Antithrombin for the prevention of intraventricular hemorrhage in very preterm infants
1. Very Preterm Infant (28-31 weeks) 2. Extremely Preterm Infant (<28 weeks) 3. Birth to 1 mo 4. Intensive Care
Provide patient population that should be included in the study
Frequency of endotracheal suctioning for the prevention of respiratory morbidity in ventilated newborns
1. Neonate 2. Birth to 1 mo 3. Mechanical ventilation 4. Endotracheal intubation
Provide patient population that should be included in the study
Transcutaneous carbon dioxide monitoring for the prevention of neonatal morbidity and mortality
1. Neonate 2. Birth to 1 mo 3. Intensive Care
Provide patient population that should be included in the study
Alternative lipid emulsions versus pure soy oil based lipid emulsions for parenterally fed preterm infants
1. Birth to 1 mo 2. Total Parenteral Nutrition 3. Parenteral nutrition 4. Preterm Infant
Provide patient population that should be included in the study
Diuretics for transient tachypnoea of the newborn
1. Transitory Tachypnea Of Newborn 2. Neonate 3. Birth to 1 mo
Provide patient population that should be included in the study
Chest shielding for prevention of a haemodynamically significant patent ductus arteriosus in preterm infants receiving phototherapy
1. Light Therapy 2. Birth to 1 mo 3. Preterm Infant
Provide patient population that should be included in the study
Specialist teams for neonatal transport to neonatal intensive care units for prevention of morbidity and mortality
1. Neonate 2. Patient Transportation 3. Birth to 1 mo 4. Intensive Care
Provide patient population that should be included in the study
Rescue high‐frequency jet ventilation versus conventional ventilation for severe pulmonary dysfunction in preterm infants
1. Lung disorder 2. Birth to 1 mo 3. Pulmonary Interstitial Emphysema Syndrome 4. Low Birth Weight Infant 5. Preterm Infant
Provide patient population that should be included in the study
Percutaneous central venous catheters versus peripheral cannulae for delivery of parenteral nutrition in neonates
1. Neonate 2. Birth to 1 mo 3. Parenteral nutrition 4. Hospitalization
Provide patient population that should be included in the study
Antimicrobial‐impregnated central venous catheters for prevention of catheter‐related bloodstream infection in newborn infants
1. Neonate 2. Birth to 1 mo 3. Central Venous Catheterisation
Provide patient population that should be included in the study
Standardised formal resuscitation training programmes for reducing mortality and morbidity in newborn infants
1. Neonate 2. Birth to 1 mo
Provide patient population that should be included in the study
Intravenous in‐line filters for preventing morbidity and mortality in neonates
1. Neonate 2. Catheterisation Venous 3. Birth to 1 mo
Provide patient population that should be included in the study
Regional (spinal, epidural, caudal) versus general anaesthesia in preterm infants undergoing inguinal herniorrhaphy in early infancy
1. Infant 1 to 23 mo 2. Inguinal Herniorrhaphy 3. Birth to 1 mo 4. Preterm Infant
Provide patient population that should be included in the study
Strategies for the discontinuation of humidified high flow nasal cannula (HHFNC) in preterm infants
1. Birth to 1 mo 2. Noninvasive Mechanical Ventilation 3. Preterm Infant
Provide patient population that should be included in the study
Elective high frequency oscillatory ventilation versus conventional ventilation for acute pulmonary dysfunction in preterm infants
1. Lung disorder 2. Intermittent Positive Pressure Breathing 3. Birth to 1 mo 4. Neonatal Respiratory Distress Syndrome 5. Low Birth Weight Infant 6. Preterm Infant
Provide patient population that should be included in the study
Methods for securing endotracheal tubes in newborn infants
1. Neonate 2. Birth to 1 mo 3. Intubation 4. Intensive Care 5. Mechanical ventilation
Provide patient population that should be included in the study
Home‐ versus hospital‐based phototherapy for the treatment of non‐haemolytic jaundice in infants at more than 37 weeks' gestation
1. Jaundice 2. Bilirubin Elevated 3. Term infant (37-41 weeks) 4. Birth to 1 mo
Provide patient population that should be included in the study
Physical activity programs for promoting bone mineralization and growth in preterm infants
1. Birth to 1 mo 2. Preterm Infant
Provide patient population that should be included in the study
Early light reduction for preventing retinopathy of prematurity in very low birth weight infants
1. Birth to 1 mo 2. Preterm Infant
Provide patient population that should be included in the study
Lung lavage for meconium aspiration syndrome in newborn infants
1. Neonate 2. Meconium Aspiration 3. Birth to 1 mo
Provide patient population that should be included in the study
Surgical versus medical treatment with cyclooxygenase inhibitors for symptomatic patent ductus arteriosus in preterm infants
1. Birth to 1 mo 2. Low Birth Weight Infant 3. Preterm Infant 4. Patent Ductus Arteriosus
Provide patient population that should be included in the study
Early trophic feeding versus enteral fasting for very preterm or very low birth weight infants
1. Very Preterm Infant (28-31 weeks) 2. Extremely Preterm Infant (<28 weeks) 3. Birth to 1 mo 4. Very Low Birth Weight Infant
Provide patient population that should be included in the study
Vasopressin and its analogues for the treatment of refractory hypotension in neonates
1. Term infant (37-41 weeks) 2. Birth to 1 mo 3. Low Blood Pressure 4. Preterm Infant 5. Acidemia
Provide patient population that should be included in the study
Nasal versus oral route for placing feeding tubes in preterm or low birth weight infants
1. Enteral nutrition 2. Birth to 1 mo 3. Low Birth Weight Infant 4. Preterm Infant
Provide patient population that should be included in the study
Hydralazine in infants with persistent hypoxemic respiratory failure
1. Term infant (37-41 weeks) 2. Neonatal Respiratory Failure 3. Birth to 1 mo 4. Preterm Infant 5. Mechanical ventilation 6. Pulmonary Arterial Hypertension
Provide patient population that should be included in the study
Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Relapsing Remitting Multiple Sclerosis 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Local corticosteroid injection versus placebo for carpal tunnel syndrome
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Carpal Tunnel Syndrome
Provide patient population that should be included in the study
Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Amyotrophic Lateral Sclerosis 5. Sialorrhoea 6. Motor Neuron Disease 7. Young Adult 19-24 years 8. Aged 65-79 years
Provide patient population that should be included in the study
Topical clonidine for neuropathic pain in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Neuropathic Pain 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Ocrelizumab for multiple sclerosis
1. Multiple Sclerosis
Provide patient population that should be included in the study
Immunoglobulin for multifocal motor neuropathy
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Multifocal Motor Neuropathy 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Siponimod for multiple sclerosis
1. Aged 80 and over 80+ years 2. Multiple Sclerosis 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Rituximab for people with multiple sclerosis
1. Aged 80 and over 80+ years 2. Multiple Sclerosis 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Memory rehabilitation for people with multiple sclerosis
1. Aged 80 and over 80+ years 2. Multiple Sclerosis 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for promoting physical activity in people with neuromuscular disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Neuromyopathy 4. Adult 19-44 years 5. Child 6-12 years 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
GLP‐1 receptor agonists for Parkinson's disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Parkinson's Disease 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Anti‐epidermal growth factor receptor therapy for glioblastoma in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Glioblastoma 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Cell‐based therapies for amyotrophic lateral sclerosis/motor neuron disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Amyotrophic Lateral Sclerosis 5. Motor Neuron Disease 6. Young Adult 19-24 years 7. Aged 65-79 years
Provide patient population that should be included in the study
Interventions for preventing falls in people with multiple sclerosis
1. Aged 80 and over 80+ years 2. Multiple Sclerosis 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years 8. Multiple chronic conditions
Provide patient population that should be included in the study
Indomethacin for intracranial hypertension secondary to severe traumatic brain injury in adults
1. Adult 19-44 years 2. Raised Intracranial Pressure 3. Middle Aged 45-64 years 4. Traumatic Brain Injury 5. Young Adult 19-24 years 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Exercise therapy for chronic fatigue syndrome
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Chronic Fatigue Syndrome 6. Aged 65-79 years
Provide patient population that should be included in the study
Psychological therapies for the prevention of migraine in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Migraine 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Mixed exercise training for adults with fibromyalgia
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Fibromyalgia 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Non‐pharmacological interventions for chronic pain in multiple sclerosis
1. Aged 80 and over 80+ years 2. Multiple Sclerosis 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years 8. Chronic Pain
Provide patient population that should be included in the study
Information provision for people with multiple sclerosis
1. Aged 80 and over 80+ years 2. Multiple Sclerosis 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Clinically Isolated Syndrome 7. Suspected Multiple Sclerosis 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Fibromyalgia 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Combination pharmacotherapy for the treatment of fibromyalgia in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Fibromyalgia 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Absorbable versus non‐absorbable sutures for skin closure after carpal tunnel decompression surgery
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Elective Surgery 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Decompression Of Median Nerve 7. Wound Closure 8. Aged 65-79 years 9. Carpal Tunnel Syndrome
Provide patient population that should be included in the study
Drug management for acute tonic‐clonic convulsions including convulsive status epilepticus in children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Tonic-clonic Seizure 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Botulinum toxin for motor and phonic tics in Tourette's syndrome
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Gilles De La Tourette's Syndrome 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years 12. Tic
Provide patient population that should be included in the study
Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease
1. Aged 80 and over 80+ years 2. Child, Preschool 2-5 years 3. Child 6-12 years 4. Infant 1 to 23 mo 5. Motor Neuron Disease 6. Fatigue 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Adult 19-44 years 10. Middle Aged 45-64 years 11. Amyotrophic Lateral Sclerosis 12. Young Adult 19-24 years 13. Birth to 1 mo
Provide patient population that should be included in the study
Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Chronic Inflammatory Demyelinating Polyradiculoneuropathy 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
alemtuzumab versus interferon beta 1a for relapsing‐remitting multiple sclerosis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Relapsing Remitting Multiple Sclerosis 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Amyotrophic Lateral Sclerosis 5. Motor Neuron Disease 6. Young Adult 19-24 years 7. Aged 65-79 years
Provide patient population that should be included in the study
Whole body vibration exercise training for fibromyalgia
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Fibromyalgia 5. Aged 65-79 years
Provide patient population that should be included in the study
Zonisamide for essential tremor
1. Aged 80 and over 80+ years 2. Essential Tremor 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Immunotherapy for diabetic amyotrophy
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Diabetic Amyotrophy 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Aerobic exercise training for adults with fibromyalgia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Fibromyalgia 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Drug therapy for chronic idiopathic axonal polyneuropathy
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Axonal Sensorimotor Neuropathy 4. Middle Aged 45-64 years 5. Idiopathic Peripheral Neuropathy 6. Chronic Disease 7. Aged 65-79 years
Provide patient population that should be included in the study
Tramadol for neuropathic pain in adults
1. Aged 80 and over 80+ years 2. Central Pain 3. Causalgia 4. Phantom Limb Pain 5. Cancer Pain 6. Polyneuropathy 7. Aged 65-79 years 8. Chronic Postoperative Pain 9. Trigeminal Neuralgia 10. Adolescent 13-18 years 11. Adult 19-44 years 12. Middle Aged 45-64 years 13. Postherpetic Neuralgia 14. Young Adult 19-24 years 15. Pain Provoked By Trauma 16. Neuropathic Pain 17. HIV infection 18. Spinal Cord Injury 19. Chronic Pain 20. Diabetic Neuropathy
Provide patient population that should be included in the study
Gabapentin for chronic neuropathic pain in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Neuropathic Pain 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Antiepileptic drugs for the treatment of infants with severe myoclonic epilepsy
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Severe Myoclonic Epilepsy In Infancy 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Chronic Inflammatory Demyelinating Polyradiculoneuropathy 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Topiramate for essential tremor
1. Aged 80 and over 80+ years 2. Essential Tremor 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Benzodiazepines for restless legs syndrome
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Restless Legs Syndrome 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Plasma exchange for Guillain‐Barré syndrome
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Guillain-barre Syndrome 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Propofol versus thiopental sodium for the treatment of refractory status epilepticus
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Status Epilepticus Due To Refractory Epilepsy 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions to prevent and treat corticosteroid‐induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. Infant 1 to 23 mo 6. Young Adult 19-24 years 7. Birth to 1 mo 8. Osteoporosis Due To Corticosteroids 9. Duchenne Muscular Dystrophy 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Aspirin for acute treatment of episodic tension‐type headache in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Episodic Tension-type Headache 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Gamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis/motor neuron disease
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Amyotrophic Lateral Sclerosis 4. Young Adult 19-24 years 5. Aged 65-79 years
Provide patient population that should be included in the study
Progesterone for acute traumatic brain injury
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Traumatic Brain Injury 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Immediate‐release versus controlled‐release carbamazepine in the treatment of epilepsy
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Epilepsy 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Antibiotics for the neurological complications of Lyme disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Adolescent 13-18 years 11. Lyme Neuroborreliosis
Provide patient population that should be included in the study
Pregabalin for essential tremor
1. Aged 80 and over 80+ years 2. Essential Tremor 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Immunotherapy for IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Polyneuropathy Associated With Monoclonal Immunoglobulin M Antibodies To Myelin-associated Glycoprotein 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
External drains versus no drains after burr‐hole evacuation for the treatment of chronic subdural haematoma in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Chronic Intracranial Subdural Hematoma 6. Aged 65-79 years
Provide patient population that should be included in the study
Pharmacological treatments for Friedreich ataxia
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Friedreich's ataxia 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Corticosteroids for Bell's palsy (idiopathic facial paralysis)
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Bell's Palsy 9. Aged 65-79 years 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Cannabinoids for fibromyalgia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Fibromyalgia 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Opioids for restless legs syndrome
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Restless Legs Syndrome 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Paracetamol (acetaminophen) for acute treatment of episodic tension‐type headache in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Episodic Tension-type Headache 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Antipsychotics for fibromyalgia in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Fibromyalgia 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Pharmacological treatment for Kleine‐Levin syndrome
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Kleine-levin Syndrome 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Corticosteroids for the treatment of Duchenne muscular dystrophy
1. Child 6-12 years 2. Young Adult 19-24 years 3. Duchenne Muscular Dystrophy 4. Adolescent 13-18 years
Provide patient population that should be included in the study
Antiepileptic drugs for the primary and secondary prevention of seizures after intracranial venous thrombosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Intracranial Venous Thrombosis 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Seizure 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Migraine 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Drugs for the acute treatment of migraine in children and adolescents
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Migraine 5. Birth to 1 mo 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Fingolimod for relapsing‐remitting multiple sclerosis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Relapsing Remitting Multiple Sclerosis 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Posture and fluids for preventing post‐dural puncture headache
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Post Spinal Headache 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for psychotic symptoms concomitant with epilepsy
1. Aged 80 and over 80+ years 2. Psychosis 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Epilepsy 6. Young Adult 19-24 years 7. Schizoaffective Disorder 8. Schizophrenia 9. Aged 65-79 years
Provide patient population that should be included in the study
Alprazolam for essential tremor
1. Aged 80 and over 80+ years 2. Essential Tremor 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Vigabatrin versus carbamazepine monotherapy for epilepsy
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Partial Seizure 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years 12. Generalized Seizure
Provide patient population that should be included in the study
Routine intracranial pressure monitoring in acute coma
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Coma 4. Adult 19-44 years 5. Child 6-12 years 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Psychological therapies for the management of chronic neuropathic pain in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Neuropathic Pain 6. Aged 65-79 years
Provide patient population that should be included in the study
Sodium channel blockers for neuroprotection in multiple sclerosis
1. Aged 80 and over 80+ years 2. Multiple Sclerosis 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Milnacipran for pain in fibromyalgia in adults
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Fibromyalgia 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for fatigue in Parkinson's disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Fatigue 6. Parkinson's Disease 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Oral nonsteroidal anti‐inflammatory drugs for neuropathic pain
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Neuropathic Pain 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Surgery for scoliosis in Duchenne muscular dystrophy
1. Adult 19-44 years 2. Child 6-12 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Scoliosis Deformity Of Spine 6. Duchenne Muscular Dystrophy 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Buprenorphine for neuropathic pain in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Neuropathic Pain 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Exercise therapy for fatigue in multiple sclerosis
1. Aged 80 and over 80+ years 2. Multiple Sclerosis 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Fatigue 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Chronic Inflammatory Demyelinating Polyradiculoneuropathy 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Venlafaxine for neuropathic pain in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Neuropathic Pain 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Pharmacological treatments for preventing epilepsy following traumatic head injury
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Traumatic Brain Injury 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Ibuprofen for acute treatment of episodic tension‐type headache in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Episodic Tension-type Headache 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Neuropsychological and psychological interventions for people with newly diagnosed epilepsy
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Epilepsy 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Drug therapy for treating post‐dural puncture headache
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Post Dural Puncture Headache 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Amitriptyline for neuropathic pain in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Neuropathic Pain 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Milnacipran for neuropathic pain in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Neuropathic Pain 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Selective serotonin reuptake inhibitors for fibromyalgia syndrome
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Fibromyalgia 6. Aged 65-79 years
Provide patient population that should be included in the study
Selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) for the prevention of tension‐type headache in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Chronic Tension-type Headache 5. Young Adult 19-24 years 6. Episodic Tension-type Headache 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Dimethyl fumarate for multiple sclerosis
1. Multiple Sclerosis 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Expanded Disability Status Scale 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Telerehabilitation for persons with multiple sclerosis
1. Aged 80 and over 80+ years 2. Multiple Sclerosis 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Migraine 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Treatment for IgG and IgA paraproteinaemic neuropathy
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. IgG Paraproteinaemic Neuropathy
Provide patient population that should be included in the study
Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Multifocal Motor Neuropathy 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Physical rehabilitation for critical illness myopathy and neuropathy
1. Aged 80 and over 80+ years 2. Critical Illness Myopathy 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Asthenia 6. Young Adult 19-24 years 7. Critical Illness Polyneuropathy 8. Aged 65-79 years
Provide patient population that should be included in the study
Early versus late antiepileptic drug withdrawal for people with epilepsy in remission
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Epilepsy 8. Young Adult 19-24 years 9. Seizure Free 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for fatigue in peripheral neuropathy
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Peripheral Nerve Disease 7. Young Adult 19-24 years 8. Fatigue 9. Aged 65-79 years 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Non‐pharmacological interventions for chronic pain in people with spinal cord injury
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Spinal Cord Injury 7. Chronic Pain
Provide patient population that should be included in the study
Aquatic exercise training for fibromyalgia
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Fibromyalgia
Provide patient population that should be included in the study
Pharmacotherapy for sleep bruxism
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Sleep-related Bruxism 6. Aged 65-79 years
Provide patient population that should be included in the study
Acetylcholinesterase inhibitor treatment for myasthenia gravis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Generalized Myasthenia 6. Aged 65-79 years 7. Myasthenia Gravis
Provide patient population that should be included in the study
Intravenous immunoglobulin for Guillain‐Barré syndrome
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Guillain-barre Syndrome 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Anticonvulsant therapy for status epilepticus
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Status Epilepticus 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Comparison of antiepileptic drugs, no treatment, or placebo for children with benign epilepsy with centro temporal spikes
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Benign Focal Epilepsy Of Childhood 5. Birth to 1 mo 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Physiotherapy for Parkinson's disease: a comparison of techniques
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Parkinson's Disease 6. Aged 65-79 years
Provide patient population that should be included in the study
Zolmitriptan for acute migraine attacks in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Migraine 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Carbamazepine for chronic neuropathic pain and fibromyalgia in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Neuropathic Pain 6. Fibromyalgia 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Chronic Pain 10. Multiple chronic conditions
Provide patient population that should be included in the study
Mycophenolate mofetil for relapsing‐remitting multiple sclerosis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Relapsing Remitting Multiple Sclerosis 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Antiviral treatment for preventing postherpetic neuralgia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Herpes Zoster 6. Aged 65-79 years
Provide patient population that should be included in the study
Interventions for preventing critical illness polyneuropathy and critical illness myopathy
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Intensive Care 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Peripheral Neuropathic Pain 5. Young Adult 19-24 years 6. Fibromyalgia 7. Chronic Painful Diabetic Neuropathy 8. Aged 65-79 years 9. Chronic Pain
Provide patient population that should be included in the study
Immunotherapy for idiopathic lumbosacral plexopathy
1. Lumbosacral plexopathy
Provide patient population that should be included in the study
Mechanical insufflation‐exsufflation for people with neuromuscular disorders
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Neuromuscular Disorders 7. Young Adult 19-24 years 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Passive movements for the treatment and prevention of contractures
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Muscle Contracture 5. Young Adult 19-24 years 6. Aged 65-79 years